Company / Cash & Equivalents
Inhibrx Biosciences, Inc. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$124.2M
FY2025
5-year range
$124.2M / $277.9M
FY2023-FY2025
Trend
-18.6%
vs FY2024
Sector context
#127 of 207
Health Care
What the data says
At $124M, Inhibrx Biosciences, Inc.'s cash & equivalents ranks #127 of 207 in the Health Care sector. Declined from $278M to $124M over the past 2 years.
Based on SEC 10-K filings.
$124M in FY2025.
Declined from $278M to $124M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#127 of 207 in Health CareTop 61% of 207This company $124.2M Sector average $669.5M
▼
-81.4% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 18.6% year-over-year.
- Ranks #127 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $124.2M | -18.6% |
| FY2024 | $152.6M | -45.1% |
| FY2023 | $277.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026